Vnitřní lékařství 8/2020

PŘEHLEDOVÉ ČLÁNKY Monitorování farmakokinetiky infliximabu u idiopatických střevních zánětů E38 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2020; 66(8): e34–e38 /  www.casopisvnitrnilekarstvi.cz 39. Minar P, Saeed SA, Afreen M, et al. Practical use of infliximab concentration monitoring in pediatric Crohn disease. J Pediatr Gastroenterol Nutr 2016; 62: 715–722. 40. Viola F, Civitelli F, Di Nardo G, et al. Efficacy of adalimumab in moderate‑to‑severe pe‑ diatric Crohn’s disease. Am J Gastroenterol 2009; 104: 2566–2571. 41. Papamichael K, van Stappen T, Vande Casteele N, et al. Infliximab concentration thre‑ sholds during induction therapy are associated with short‑term mucosal healing in pati‑ ents with ulcerative colitis. Clin Gastroenterol Hepatol 2016; 14: 543–549. 42. Singh N, Rosenthal CJ, Melmed GY, et al. Early infliximab trough levels are associated with persistent remission in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2014; 20: 1708–1713. 43. Ding NS, Hart A, de Cruz P. Systematic review: predicting and optimising response to anti‑TNF therapy in Crohn’s disease – algorithm for practical management. Aliment Phar‑ macol Ther 2016; 43: 30–51. 44. Cornillie F, Hanauer SB, Diamond RH, et al. Postinduction serum infliximab trough le‑ vel and decrease of C‑reactive protein level are associated with durable sustained respon‑ se to infliximab: a retrospective analysis of the ACCENT I trial. Gut 2014; 63: 1721–1727. 45. Amin A, Prosser C, Kroeker K, et al. Using infliximab trough levels and fecal calprotectin le‑ velstogethertoguideclinicaldecisionshasthepotentialto improveoutcomes in inflammatory bowel disease patients onmaintenance infliximab therapy. Gastroenterology 2016; 150: S422. 46. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63: 1258–1264. 47. Steenholdt C, Frederiksen MT, Bendtzen K et al. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol 2015; 50: 483–489. 48. Papamichael K, Vande Csteele N., Billiet T, et al. Early therapeutic drug monitoring for prediction of short‑term muckal healing in pacients with ulcerative colitis treated with infliximab. Gastroenterology 2015; 148: S848. 49. Bortlík M, Ďuricová D, Malíčková K, et al. Infliximab trough levels may predict sustained response to infliximab in patients with Crohns disease. JCC 2013; 7: 736–743. 50. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immuno‑ suppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s di‑ sease. Gut 2007; 56: 1226–1231. 51. Papamichael K, Vande Casteele N, Ferrante M, et al. Therapeutic drug monitoring du‑ ring induction of anti‑tumor necrosis factor therapy in inflammatory bowel disease: defi‑ nic a therapeutic Windows. Inflamm Bowel Dis 2017; 23:, 1510–1515. 52. Pariente B, de Chambrun GP, Krzysiek R, et al. Trough levels and antibodies to inflixi‑ mab may not predict response to intensification of infliximab therapy in patients with in‑ flammatory bowel disease. Inflamm Bowel Dis 2011; 18: 1199–1206. 53. Roblin X, Williet N, Peyrin‑Biroulet L. Thiopurin metabolism in the area of combothe‑ rapy. Inflamm Bowel Dis 2016; 22: 1496–1501. 54. Del Tedesco E, Paul S, Marotte H. Azathioprine dose reduction in inflammatory bowel di‑ sease patients on combination therapy: A prospekte study. DDW 2016, oral presenation 693. 55. D’Haens G, Vermeire S, Lambrecht G, et al. OP029 Drug‑concentration versus symptom­ ‑driven dose adaptation of Infliximab in patients with active Crohn’s disease: a prospecti‑ ve, randomised, multicentre trial (Tailorix). ECCO; 2016. 56. Papamichael K, Chachu KA, Vajravelu RK, et al. Improved long term outcomes of pati‑ ents with inflammatory bowel disease receiving proactive compared with reactive monito‑ ring of serum concentrations of infliximab. Clin Gastroenterol Hepatol 2017; 15: 1580–1588. 57. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualised therapy is more cost­ ‑effective than dose intensification in patients with Crohn’s disease who lose response to anti‑TNF treatment: a randomised, controlled trial. Gut 2014; 63: 919–927. 58. Steenholdt C, Brynskov J, Thomsen OO, et al. Individualized therapy is a long‑term cost‑effective method compared to dose intensification in Crohn’s disease patients fai‑ ling infliximab. Dig Dis Sci 2015; 60: 2762–2770. 59. VandeCasteeleN,KhannaR,LevesqueBG,etal.Therelationshipbetween infliximabconcen‑ trations,antibodiesto infliximabanddiseaseactivity inCrohn’sdisease.Gut2015;64:1539–1545. 60. Flamant M, Roblin X. Could therapeutic drug monitoring of antiTNF‑alpha be use‑ ful to consider a de‑escalation of treatment? Expert Opin Biol Ther 2015; 15: 1657–1660. 61. Louis E, Mary JY, Vernier‑Massouille G, et al. Maintenance of remission among patients with Crohn’s disease on antimetabolite therapy after infliximab therapy is stopped. Gas‑ troenterology 2012; 142: 63–70. 62. Papamichael K, Vande Casteele N, Gils A, et al. Long‑term outcome of patients with Crohn’s disease who discontinued infliximab therapy upon clinical remission. Clin Gast‑ roenterol Hepatol 2015; 13: 1103–1110. 63. Ben‑Horin S, Waterman M, Kopylov U, et al. Addition of an immunomodulator to in‑ fliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2013; 11: 444–447. 64. D’Haens G, Vermeire S, Lambrecht G, et al. GETAID. Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, en‑ doscopic, and corticosteroid‑free remission in patients with active luminal Crohn’s disea‑ se. Gastroenterology 2018; 154: 1343–1351. 65. Papamichael K, Vajravelu RK, Vaughn BP, et al. Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis 2018; 12: 804–810. 66. Bortlík M, Ďuricová D, Machková N, et al. Impact of anti‑tumor necrosis factor alpha antibodies administered to pregnant woman with inflammatory bowel disease on long­ ‑term outcome of exposé children. Inflamm Bowel Dis 2014; 20: 495–501. 67. Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. In‑ flamm Bowel Dis 2016; 22: 1999–2015. 68. Steenholdt C, Brynskov J, Thomsen OO, et al. Implications of infliximab treatment failure and influence of personalized treatment on patient‑reported health‑related quality of life and productivity outcomes in Crohn’s disease. J Crohns Colitis 2015; 9: 1032–1042. 69. Velayos FS, Kahn JG, Sandborn WJ, et al. A test‑based strategy is more cost effective than empiric dose escalation for patients with Crohn’s disease who lose responsiveness to infliximab. Clin Gastroenterol Hepatol 2013; 11: 654–666. 70. Negoescu DM, Enns EA, Swanhorst B, et al. Proactive vs reactive Therapeutic drug mo‑ nitoring of infliximab in Crohns disease: A cost‑effectivness analysis in a simulated cohort. Inflamm Bowel Dis 2019; 50: 1–9.